Mi SciELO
Servicios Personalizados
Revista
Articulo
Indicadores
- Citado por SciELO
- Accesos
Links relacionados
- Citado por Google
- Similares en SciELO
- Similares en Google
Compartir
Revista de la OFIL
versión On-line ISSN 1699-714Xversión impresa ISSN 1131-9429
Resumen
FORTES-GONZALEZ, MS et al. Medicines with high economic impact in the hospital setting. Rev. OFIL·ILAPHAR [online]. 2022, vol.32, n.2, pp.137-155. Epub 13-Feb-2023. ISSN 1699-714X. https://dx.doi.org/10.4321/s1699-714x2022000200005.
Objectives:
High economic impact medicines (HIM) are challenging health services of the European countries. Nevertheless, there is no consensus on what constitutes a HIM. The aim of the study is to compile a list of HIM dispensed by Spanish hospital pharmacy services and to analyze the situation regarding those medicines in Spain.
Methods:
Drugs with a cost higher than €10,000 per year (HCM) or high volume of consumption (HVM) were considered HIM. The ex-factory price (PVL) per defined daily dosage or prescribed daily dose was calculated.
Results:
A total of 147 active ingredients were HCM, corresponding to ATC code: L (69.4%), J (10.9%) and A (10.2%). Mean daily PVL of HCM was € 218.6 (28.6-2,892.5). 38.8% were innovative drugs, 26.5% were orphan products and 34.0% were biological drugs. A total of 16 medicines (5.8%) were priced more than € 10,000/pack. The HVM belonged mainly to group L (45.0%) and J (35.0%). Average daily PVL of HVM was € 154.4 (1.1-1,629.3). 35% were first-in-class drugs, 5% orphan medicines and 60% biological drugs.
Conclusions:
This study shows that a large number of HIM are dispensed by the hospital pharmacy services, mainly antineoplastic and antiinfective drugs. Although the minimum daily PVL to consider a medicine as HCM was € 27.4. The average daily price of HCM was >€ 200. However, given the high consumption of some drugs, medicines with a daily cost as low as € 1.1 can be considered HIM. A new category of HCM, ultra-premium-priced medicines, could be established for drugs with a cost higher than € 10,000 per pack.
Palabras clave : Economics; pharmaceutical; health policy; high cost; technology; drug costs.